Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab in relapsed or refractory B-cell non-Hodgkin lymphoma
2024-511747-25-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 2, open-label trial of odronextamab in mature B-cell lymphoma, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and 2 more (5 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Overall response rate. Planned start Dec 2019; status: authorised.
02
Drugs
odronextamab
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2024-511747-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511747-25-00.